WHO ICTRP trial
A study to determine the ability of AF-219 to affect the cough reflex in healthy…
EUCTR2015-000464-34-GB · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2015-000464-34-GB |
|---|---|
| Public title | A study to determine the ability of AF-219 to affect the cough reflex in healthy volunteers and in people affected by long-term coughing |
| Scientific title | A Study to Assess the Effect of AF-219 on Cough Reflex Sensitivity in Both Healthy and Chronic Cough Subjects |
| Primary sponsor | Afferent Pharmaceuticals, Inc. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | United Kingdom |
| Conditions | Chronic Cough;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] |
| Interventions | Product Code: AF-219 Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use |
| Registration date | Mar 26, 2015 |
| Target size | 54 |
| Secondary IDs | AF219-015 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: